SAN FRANCISCO, Nov. 11 /PRNewswire-FirstCall/ -- Osteotech, Inc. , a leader in the emerging field of biologic products for regenerative healing, today announced it is highlighting three procedure-specific MagniFuse(TM) bone grafting products for different spine therapy areas at the North American Spine Society (NASS) 2009 Annual Meeting, taking place November 10th through 14th in San Francisco, California. To date MagniFuse has been used in 40 spinal surgeries in the United States.
“Our strategy is to utilize our platform technologies to develop procedure-specific products to address critical unmet surgical needs and we are very excited to be highlighting our MagniFuse platform at NASS,” said Sam Owusu-Akyaw, Osteotech’s President and Chief Executive Officer. “By utilizing our MagniFuse product line in posterior cervical, posterolateral and spinal deformity procedures, Osteotech is targeting a significant segment of the spinal therapy area. Feedback from surgeons that have used MagniFuse to date indicates the differentiated characteristics and capabilities supported by our MagniFuse technology have been well received, and we believe we are strongly positioned to become a market leader.”
MagniFuse is a patented, next-generation technology platform that supports a family of high-performance, procedure-specific products that provide for simplified, precision grafting when injury or disease creates a need for bone fusion or new bone growth.
“In addition, we are also looking forward to showcasing our leading-edge FacetLinx(TM) Fusion Technology and Plexur M(TM) Innovative Grafting at NASS,” continued Mr. Owusu-Akyaw. “Similar to MagniFuse, these products have received very positive responses in the market and we believe they will both play an important role in our future success. Our goal at Osteotech is to continue to commercialize proprietary biologics designed to address the unmet needs of the surgeon community and we believe these introductions illustrate our ability to successfully execute this strategy. We are pleased to share them directly with the physician community through NASS this week.”
New MagniFuse Technology Products
Osteotech is showcasing three procedure-specific forms for three different spine therapy areas in the Company’s booth at NASS: PC (posterior cervical), SD (spinal deformity) and PL (posterolateral).
MagniFuse Technology Platform
Osteotech’s MagniFuse technology platform and related products offer unique, differentiating features compared with other bone grafts on the market:
Plexur M Innovative Grafting
Plexur M, a biocomposite combination of cortical bone fibers and resorbable polymers, may be used in a variety of orthopedic procedures as a bone void filler. Developed utilizing the Company’s proprietary Plexur(R) technology, Plexur M offers a number of unique characteristics for orthopedic surgeons:
The Plexur technology platform is a unique and patented combination of polymer and cortical bone fibers that supports a family of procedure-specific products targeted for use in a variety of orthopedic surgeries. Plexur technology-based products have been clinically shown to completely resorb into the body within six to twelve months and to be replaced by host bone. Plexur technology offers improved handling and an effective osteoconductive matrix with high levels of porosity that provides a broad surface area for new cell growth. Plexur is supported by more than 20 patents and patent applications and is the platform technology that supports Plexur P(TM) used in a variety of trauma and reconstructive surgeries and focused on foot and ankle procedures as well as Plexur M.
FacetLinx Fusion Technology
Facet joint disorders are among the most common of all the recurrent, disabling low back problems that have serious symptoms and disability. FacetLinx is a patent-pending spinal allograft product that treats mechanical and facet-driven back pain by fixating the facet joints or may augment standard instrumented and non-instrumented fusion, offering patients stability with minimum additional risks. FacetLinx offers a number of differentiating advantages over other facet fusion devices:
About Osteotech
Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing biologic solutions for regenerative medicine to support surgeons and their patients through the development of innovative therapy-driven products that alleviate pain, promote regenerative and biologic healing and restore function. For further information regarding Osteotech or this press release, please go to Osteotech’s website at www.osteotech.com.
Certain statements made throughout this press release that are not historical facts are forward-looking statements (as defined in the Private Securities Litigation Reform Act of 1995) regarding the Company’s future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company’s ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company’s periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of November 11, 2009 and the Company does not intend to update this information.
CONTACT: Company: Mark H. Burroughs, +1-732-542-2800, Investors: Jennifer
Beugelmans, +1-646-596-7473, Media: Dan Budwick, +1-973-271-6085, all of
Osteotech, Inc.
Web site: http://www.osteotech.com/
